A recent study presented at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans highlights promising results for a new treatment in managing type 1 diabetes. The treatment, known as acmopatide (CT-868), is a once-daily injection that acts as a dual glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonist (GLP-1/GIP RA). This innovative approach has shown potential in improving blood glucose management, reducing body weight, and decreasing insulin requirements in patients with type 1 diabetes.

Study Details and Findings

The phase 2 trial was a randomized, placebo-controlled study involving 111 adults with type 1 diabetes who were classified as having overweight or obesity. Participants were assigned to receive varying doses of acmopatide or a placebo. The primary endpoint was the change in A1C levels, a measure of average blood glucose, from baseline to week 16. Secondary endpoints included changes in body weight, insulin dose requirements, and continuous glucose monitoring metrics.

The findings revealed that treatment with acmopatide led to a reduction in A1C levels by 0.34% from baseline in patients receiving a 4.1mg dose. Additionally, 56% of these participants achieved an A1C below 7%, the recommended target for diabetes management. The study also noted a dose-dependent weight loss of up to 7% and a reduction in insulin use by up to 15% compared to the placebo group. Importantly, the treatment was generally well tolerated with no significant safety concerns reported.

Implications for Diabetes Management

Dr. Klara Klein, the lead author of the study, emphasized the significance of these findings, stating that despite advances in diabetes care, treatment options beyond insulin remain limited for those with type 1 diabetes. The potential of acmopatide as the first incretin therapy specifically developed for type 1 diabetes could expand treatment options, improve glycemic control, support weight management, and ultimately reduce the burden of diabetes-related complications.

The American Diabetes Association’s 2026 Scientific Sessions, where this study was presented, is the world’s largest scientific meeting focused on diabetes research, prevention, and care. The event gathers thousands of leading physicians, scientists, and healthcare professionals to share cutting-edge research and treatment advancements.

Original reporting: KTBS 3 (Shreveport) — read the source article.